Comparison of clinical-economic evaluation of cabazitaxel and abiraterone for prostate cancer based on the results of clinical trials and real world data

Качественная клиническая практика

A. A. Kurylev¹  A. S. Kolbin²  A. V. Pavlysh² 

[1] Saint Petersburg State University, Saint Petersburg, Russia;First Pavlov State Medical University of Saint Petersburg, Saint Petersburg, Russia;

关键词: клинико-экономический анализ;    рак предстательной железы;    кабазитаксел;    абиратерон;    health technology assessment;    prostate cancer;    cabazitaxel;    abiraterone;   

DOI  :  

来源: DOAJ

【 摘 要 】

Comparative health technology assessment has been performed for evaluation of hormone resistant prostate cancer 2-d line chemotherapy schemes with cabazitaxel or abiraterone after docetaxel treatment. There were no found the difference between effects of both variations of treatment based on randomized clinical trials results. In the same time, the real world data shown more efficacy of cabazitaxel vs abiraterone based on non-progressive survival rate. Clinical-economic impact of both schemes was equal in relations with clinical trials data. Modelling economic analysis of real world data describes budget saving in case of using cabazitaxel vs abiraterone. Cost of cabazitaxel usage is less vs abiraterone in relations with non-progressive survival rate. Cost saving can use for the treatment of additional 17 patients with cabazitaxel (on each 100 pts.).

【 授权许可】

Unknown